Related Experiment Video
Updated: Sep 28, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Pheno- and genotyping the prescription of drugs metabolized by CYP2D6
G V Ramenskaya1, A Yu Savchenko, A A Agafonov
1Laboratory for Drug Development, Study, Introduction, Manufacture, and Marketing, Russian Academy of Medical Sciences, Moscow.
Abstract:
Mutant alleles CYP2D63 and CYP2D64 were detected by PCR in 33 individuals. All examinees were given 50 mg methoprolol (orally). Plasma concentrations of the drug and its major metabolite was determined by high performance liquid chromatography and arterial pressure and heart rate were monitored. The rate of methoprolol metabolism was significantly lowered in subjects with CYP2D64 mutation. This determined blood pressure decrease and bradycardia in these subjects after drug intake.
Related Concept Videos
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
